COMPLIA: A 12-MONTH PROSPECTIVE, MULTICENTRE, NON-INTERVENTIONAL STUDY TO EVALUATE TREATMENT ADHERENCE AND TREATMENT SATISFACTION IN A GROWTH HORMONE DEFICIENT PAEDIATRIC POPULATION TREATED WITH NUTROPINAQ A SOMATROPIN ANALOGUE.

Background/aims: Growth hormone deficiency (GHD) in children and adolescents is managed with growth hormone (GH) therapy and aims to achieve optimal height development. However, treatment adherence can be poor, reducing the likelihood of a successful outcome. Adherence varies between geographic regions.

Metabolic monitoring of obese children born small for gestational age.

Introduction: The "catch-up growth" phenomenon in children born small for gestational age (SGA) has been linked to early onset obesity with the subsequent emergence of metabolic syndrome (MetS) or its components. It has been postulated that the prevalence of MetS and its components increases strongly with age.

Materials And Methods: A retrospective study was carried out over a 5 year period (2007-2011) to determine long-term metabolic complications in obese children born with normal weight for gestational age (appropriate for gestational age: AGA) and SGA.

Is small for gestational age status associated with an increased risk of atherogenesis?

Abstract: The "catch-up growth" phenomenon in children born small for gestational age (SGA) has been linked to early onset obesity with the subsequent emergence of metabolic syndrome (MetS). The intima media thickness of the common carotid artery (CIMT) is a well-known marker of subclinical atherosclerosis.

Aim: to determine the association between being born SGA and CIMT, a measure of atherogenesis and to investigate metabolic risk factors which impact on CIMT in obese children.

Biosimilars: controversies as illustrated by rhGH.

Unlabelled: Abstract Background and scope: Similar biological medicinal products, also called 'biosimilars', are copies of biopharmaceutical products whose patent has expired. Whether biosimilars are truly comparable and interchangeable with their reference biopharmaceutical products in terms of quality, efficacy and tolerability, is still a matter of debate. This review discusses the controversies related to the criteria for regulatory approval of biosimilars.

[Nifedipine poisoning in a child].

The present paper concerns the problem of nifedipine poisoning at a 2-year- [correction of 1-year-] and 4-month-old boy, developed after ingestion of 15 tablets with 150 mg active substance. The medical care was represented by: a) gastric lavage with evacuation of stomach content and b) repeated administration of calcium with permanent monitoring of cardiac rhythm, electrocardiography and blood pressure. The evolution was very good with total disappearance of clinical signs in first 6 hours after admission.